Catalyst
Slingshot members are tracking this event:
TGV-Inhalonix Receives Orphan Drug Status for its Novel Antibiotic to Treat Resistant Infections in Cystic Fibrosis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TGV-Inhalonix | Community voting in process | |||||
Additional Information
The FDA granted the Orphan Drug Designation for Mul-1687 after reviewing multiple experimental research findings by TGV-Inhalonix. TGV-Inhalonix said its research indicates Mul-1867 holds promise for addressing unmet need for improved treatment of antibiotic-resistant pulmonary infections.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 12, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bacterial Lung Infections, Cystic Fibrosis, Mul-1687, Antibiotic-resistant Pathogens, Antibiotic-resistant Pulmonary Infections, Ventilator-associated Pneumonia, Respiratory Failure, Lung Function, Copd Patients, Respiratory Tract Infections
